This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Brey, R. Articles by Escalante, A. Search for Related Content PubMed PubMed Citation Articles by Brey, R. Articles by Escalante, A. Social Bookmarking                         What's this?

Review : Neurological manifestations of antiphospholipid antibody syndrome

Department of Medicine, Divisions of 'Neurology University of Texas Health Science Center

A. Escalante

Clinical Immunology, University of Texas Health Science Center, San Antonio, Texas, USA

Thrombosis, thrombocytopenia, recurrent fetal loss and a variety of non-thrombotic neurological disorders have all been associated with antiphospholipid antibodies (aPL). Cerebral ischemia associated with aPL is the most common arterial thrombotic manifestation. Depression, cognitive dysfunction, depression and psychosis have all been associated with aPL. The presumed pathophysiologic mechanism underlying these manifestations is thought to be a result of cerebral ischemia in some, but not all cases. Seizures, chorea and transverse myelitis all appear to be associated with aPL. An interaction between aPL and central nervous system cellular elements rather than aPL-associated thrombosis seems to be a more plausible mechanism for these clinical manifestations. Migraine on the other hand, does not appear to be associated with aPL in either lupus or non-lupus populations. Neuroimaging studies show an increased frequency of brain abnormalities in patients with aPL, but none appear to be specific. The best treatment strategy for preventing neurological manifestations of aPL is not fully defined. For thrombotic manifestations, both antiplatelet and anticoagulant therapies have been suggested. In some patients, immunosup pressant therapy has been used. For non-thrombotic manifestations, some combination of immunosuppressant therapy and symptomatic treatment may be warranted.

Key Words: antiphospholipid syndrome • lupus anticoagulant • anticardiolipin antibody • anti-β2 glycoprotein 1 • thrombosis • stroke • migraine • seizures • chorea • transverse myelitis • treatment

Lupus, Vol. 7, No. 2 suppl, S67-S74 (1998)
DOI: 10.1177/096120339800700216


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				X Lu, Y Gu, Y Wang, S Chen, and S Ye Prognostic factors of lupus myelopathy Lupus, April 1, 2008; 17(4): 323 - 328. [Abstract] [PDF]

				K Spengos, P Manta, K Sfagos, and D Vassilopoulos Letter to the Editor Lupus, July 1, 2004; 13(7): 555 - 556. [PDF]

				A Katzav, J Chapman, and Y Shoenfeld CNS dysfunction in the antiphospholipid syndrome Lupus, December 1, 2003; 12(12): 903 - 907. [Abstract] [PDF]

				J Chapman, J H Rand, R L Brey, S R Levine, I Blatt, M A Khamashta, and Y Shoenfeld Non-stroke neurological syndromes associated with antiphospholipid antibodies: evaluation of clinical and experimental studies Lupus, July 1, 2003; 12(7): 514 - 517. [Abstract] [PDF]

				Y Shoenfeld, A Nahum, A D Korczyn, M Dano, R Rabinowitz, O Beilin, C G Pick, L Leider-Trejo, L Kalashnikova, M Blank, et al. Neuronal-binding antibodies from patients with antiphospholipid syndrome induce cognitive deficits following intrathecal passive transfer Lupus, June 1, 2003; 12(6): 436 - 442. [Abstract] [PDF]

				S Shrot, A Katzav, A D Korczyn, Y Litvinjuk, R Hershenson, C G Pick, M Blank, J Zaech, Y Shoenfeld, P Sirota, et al. Behavioral and cognitive deficits occur only after prolonged exposure of mice to antiphospholipid antibodies Lupus, November 1, 2002; 11(11): 736 - 743. [Abstract] [PDF]